Evaluation of two doses of etoricoxib, a COX-2 selective non-steroidal anti-inflammatory drug (NSAID), in the treatment of Rheumatoid Arthritis in a double-blind, randomized controlled trial
Crossref DOI link:
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Kivitz, Alan J.
Peloso, Paul M.
Funding for this research was provided by:
unspecified valid from 2016-08-08